Status:
COMPLETED
Increasing Use of the Vaccine Against Herpes Zoster/Shingles at NYULMC and Bellevue Hospital
Lead Sponsor:
NYU Langone Health
Collaborating Sponsors:
Merck Sharp & Dohme LLC
Conditions:
Herpes Zoster
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
The purpose of this study is to determine if vaccination rate of eligible patients at a major urban public hospital will increase by having ophthalmologists screen patients for eligibility and a nurse...
Detailed Description
Patient vaccination behaviors will be assessed after 100 doses of the Zostavax vaccine are provided to underserved patients screened by ophthalmologists at the General Eye Clinic at a public hospital ...
Eligibility Criteria
Inclusion
- 60 years of age or older
- Absence of evidence of immune compromise in the medical record
- Ability to speak and read English, Spanish or Chinese and give informed consent
Exclusion
- Vulnerable patients, including the cognitively impaired, prisoners and employee
- FDA contraindications for Zostavax vaccine
Key Trial Info
Start Date :
January 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
170 Patients enrolled
Trial Details
Trial ID
NCT01483378
Start Date
January 1 2012
End Date
February 1 2012
Last Update
August 9 2013
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Bellevue Hospital
New York, New York, United States, 10016
2
NYU Langone Medical Center
New York, New York, United States, 10016